Invima approves the use of the AstraZeneca vaccine in Colombia

The National Institute of Medicinal Products and Food, Invite, confirmed on the night of this March 23rd that it has approved the emergency use of the AstraZeneca vaccine, with which biological dicho can be ingested and applied legally within the market area of ​​the National Vacation Plan.

In agreement with Julio Aldana, Director of the Institute, “we would like to take this note to the countries, In time, the Invima approved the use of the AstraZeneca vehicle de cara al National Plan de Vacunación ”.

Please note that the Minister of Health and Social Protection has confirmed the approval of dicha approval on the night of this Friday, February 19, the one who wants to decide that the pharmacological vigilance agency will open four days in which to have a good visit.

About the speed with which the biological was approved, Aldana explained that “In the market for this sanitary regulation, there is a temporary dialogue figure that allows us to use other countries to access the data of their vacancies quickly”, because the Invima tenien de antemano, information necessary to allow the wording of dicha formula, the only thing that is necessary is that the pharmaceutical hiccup the solicitation of emergency use.

For this reason, the official concluded, he hopes that “very soon Moderna and Janssen will issue an authorization for the emergency service and incorporate it into this evacuation plan”.

Following the announcement in December by the Gobierno National, the approval for AstraZeneca is expected during the first days of 2021, during a batch of 10 days from the presentation of the approval of the approval. Prohibition of probes, the pharmaceutical decision hopes to meet the OMS certification to enter the country.

Cabe mentions that, it is calculated that a biological dicho counts with a 70 per cent of efficiency and fue the first vaccine to log the approval of the United Kingdom, the December finals of the past year.

The emergency use sanitary authorization is a temporary and conditional figure, “separate from the sanitary register, for biological medicines and chemical synthesis destined for diagnostic, the prevention and treatment of COVID-19 that accounts with a clinical study that responds to the generation of evidence of efficacy and security of the product in the market of the disposition by the Decree 1787 of December 29 of 2020 ”.

At the moment, the biological units that are authorized by Pfizer are circulating in the country since the 15th of February and SinoVac, which took place on the 20th of February.

Fue confirmed by the pair with the Pfizer and the same shape: 10 million directly sold to British Pharmaceuticals, linked to Oxford University, and another descending portion, obtained by means of an accelerator mechanism for access to the joints against the covid-19, COVAX.

It is a more traditional version of the vacancies, as well as others such as hepatitis B, Ebola and influenza, working with an adenovirus-based platform, which does not produce disease. ‘Inside it sets up genetic information for what it produces and generates a reaction that prevents the virus from generating the infection which enters the cell, ”explained Minister Ruiz at the moment.

Like the Janssen, and SinoVac, requires a refrigeration of between 2 ° and 8 °, which can be distributed in the 37 regions of the Ministry of Health in the country, which have free quarters with capacity to increase up to 70 million doses. Of all, Iran has 3,000 application points throughout the national territory.

Lee also: